LONDON, March 27 /PRNewswire/ -- Responding to guidance issued today by the Medicines and Healthcare products Regulatory Agency (MHRA), advising that cough and cold treatments should not be used for infants and children under 2 years of age, the Royal Pharmaceutical Society of Great Britain (RPSGB) has called on pharmacists to review how such products are stored and sold.

RPSGB's Director of Practice & Quality Improvement, David Pruce, says:

MILAN, Italy, March 27 /PRNewswire/ --

- Degarelix Suppressed Testosterone Within Three Days in 96% of Patients

Data from a Phase III study presented at the 23rd Annual European Association of Urology Congress demonstrated that the investigational GnRH blocker, degarelix, produced a significant reduction in levels of testosterone (1),(2) within three days in more than 96% of study patients.(2)

The new data show that degarelix provided an extremely fast effect on testosterone levels, close to the immediate effect achieved with surgery (orchidectomy).(2),(3)

FREISING-WEIHENSTEPHAN, Germany, March 27 /PRNewswire/ --

- New Investment Round Led by OrbiMed Advisors, World's Largest Healthcare Investment Firm

Pieris AG, a bio-pharmaceutical company developing Anticalins(R), a novel class of targeted human protein therapeutics, announced today the closing of a Series B financing round.

INGELHEIM, Germany, March 27 /PRNewswire/ --

- For Media Outside the US

Boehringer Ingelheim today announced that the European Commission has granted marketing authorisation of the novel, oral direct thrombin inhibitor, Pradaxa(R) (dabigatran etexilate) in all 27 EU member states. It is anticipated that Pradaxa(R) will be launched in Germany and the United Kingdom in the coming weeks.

(Photo: http://www.newscom.com/cgi-bin/prnh/20080327/298676a )

(Photo: http://www.newscom.com/cgi-bin/prnh/20080327/298676b )

Pradaxa(R) is approved for the prevention of venous thromboembolic events in adults who have undergone elective total hip or total knee replacement surgery.

GOTHENBURG, Sweden, March 27 /PRNewswire/ -- Cellectricon, a leading provider of screening solutions for drug discovery, today announced the launch of the new Cellaxess(R)HT System. The world's first fully automated high throughput transfection system enables reagent-free delivery of genetic material to a wide range of biologically relevant cell types. The system will be introduced at the SBS 14th Annual Conference and Meeting in St. Louis, MO, USA, April 6-10.

Cellectricon has developed Cellaxess(R)HT in close collaboration with leading research groups to meet the increasing demand for a technology capable of genome-wide RNAi screening.

TOKYO, March 27 /PRNewswire/ --

NTT Communications (NTT Com) announced today the launch of its Global Unified Threat Managed (Global UTM) service, which will provide Arcstar(TM) Global IP-VPN customers with integrated services for planning, constructing, managing and implementing effective protection against network security threats.

Global UTM utilizes a range of security technologies to provide IP-VPNs with comprehensive protection against threats. A service package typically includes modules for integrated firewall, IPSec VPN, iIntrusion Protection System(IPS) antivirus content and spam filtering.

OXFORD, England, March 27 /PRNewswire/ -- Commerce Decisions, a leading provider of software and services to support through-life procurement and delivery processes is working with South Tyneside and Gateshead Councils (STaG) to support the procurement process behind their multi-million pound investment in schools. This investment is part of the Building Schools for the Future (BSF) programme, which is the UK Government's biggest investment in improving schools for over 50 years.

In Northern Vietnam, neonatal mortality is almost four times higher than the official figure according to a report published today in the open access journal BMC International Health and Human Rights. This under-reporting could mean neonatal healthcare in the country is massively under-funded.

Lars-Ake Persson, Mats Målqvist and colleagues at Uppsala University, along with researchers at Karolinska University Hospital, Stockholm, Sweden, are working with the Uong Bi General Hospital, in Quang Ninh, and the Vietnamese Ministry of Health, in Hanoi, on the question of unreported births and neonatal deaths.

An international collaboration is creating an innovative "freely-accessible, high resolution" digital interactive archive of William Shakespeare's pre-1641 quartos; living artifacts that tell the story of how Shakespeare's Hamlet, Henry V, King Lear, Midsummer Night's Dream, and Romeo and Juliet, to name just a few, first circulated.

The University of Maryland's Institute for Technology in the Humanities (MITH) Director Neil Fraistat says, "The quartos themselves offer crucial evidence about what actually was performed" by Shakespeare's troupe.

Because Shakespeare himself did not authorize a printed edition of his plays, what was published at the time represented what others heard, memorized or took from the marked-up "foul papers" of a particular production.